A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Based on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
There are important differences in and misconceptions about the prevalence, clinical presentation and treatment of skin of color versus Caucasian psoriasis patients. Dermatologist Andrew F. Alexis, M.D., M.P.H., share his insight about what dermatologists need to know when treating psoriasis skin of color patients.
There’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.